Cargando…
Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
We analyzed the treatment of newly diagnosed and relapsed/refractory multiple myeloma (NDMM/RRMM) patients with del(17p). Thirteen prospective studies that evaluated 3,187 MM patients, including 685with del(17p), were included in our meta-analysis. The incidence of del(17p) in NDMM and RRMM patients...
Autores principales: | Liu, Jinghua, Yang, Hui, Liang, Xiaochan, Wang, Yuxin, Hou, Jian, Liu, Yanqin, Wang, Jigang, Zhou, Fan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617517/ https://www.ncbi.nlm.nih.gov/pubmed/28977957 http://dx.doi.org/10.18632/oncotarget.18722 |
Ejemplares similares
-
Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials
por: Shah, Chintan, et al.
Publicado: (2018) -
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis
por: Xu, Linchun, et al.
Publicado: (2023) -
Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Ling, et al.
Publicado: (2019) -
Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma
por: Wang, Pei, et al.
Publicado: (2023) -
The Prognostic Role of Cyclin D1
in Multiple Myeloma: A Systematic
Review and Meta-Analysis
por: Jiang, Yuwen, et al.
Publicado: (2022)